Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring
|ClinicalTrials.gov Identifier: NCT01752231|
Recruitment Status : Terminated (Feasibility issues.)
First Posted : December 19, 2012
Last Update Posted : December 21, 2017
|Condition or disease|
I. Optimize and develop functional DCE-MRI pulse sequences, which involve the injection of MRI-visible contrast agents, for imaging in the head/neck, abdominal and pelvic regions.
II. Determine the ideal radiofrequency (RF) coil setup to maximize signal to noise ratio of the optimized pulse sequences.
III. Distill the findings of specific aims 1 and 2 into streamlined protocols that can be used in subsequent studies for cancer phenotyping and treatment monitoring in a quantitative manner.
IV. To establish a virtual reference image repository for future studies.
OUTLINE: Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Official Title:||Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring|
|Actual Study Start Date :||July 23, 2013|
|Actual Primary Completion Date :||August 29, 2017|
|Actual Study Completion Date :||August 29, 2017|
DCE-MRI (dynamic contrast-enhanced MRI)
Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
- Dynamic contrast-enhanced MRI (DCE-MRI) as a measure of tumor treatment response. [ Time Frame: 1 year ]Analysis of DCE-MRI data will be by semi-quantitative metrics such as the area under the curve (AUC), the slopes of contrast agent uptake and washout curves as well as peak contrast agent uptake. Alternatively quantitative metrics based upon pharmacokinetic modeling will be derived. The model is the 2-compartment Kety model from which volume transfer constants between compartments and volume of the tissue compartments can be calculated.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01752231
|United States, California|
|City of Hope Medical Center|
|Duarte, California, United States, 91010|
|Principal Investigator:||Jinha Park, MD, Ph.D.||City of Hope Medical Center|